Free shipping on all orders over $ 500

Acalabrutinib

Cat. No. M5306
Acalabrutinib Structure
Synonym:

ACP-196

Size Price Availability Quantity
5mg USD 45  USD45 In stock
10mg USD 75  USD75 In stock
25mg USD 120  USD120 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

In vitro: In the in vitro signaling assay on primary human CLL cells, acalabrutinib inhibits tyrosine phosphorylation of downstream targets of ERK, IKB, and AKT. Acalabrutinib demonstrates higher selectivity for BTK with IC50 determinations on nine kinases with a cysteine residue in the same position as BTK. Importantly, unlike ibrutinib, acalabrutinib does not inhibit EGFR, ITK, or TEC. acalabrutinib has no effect on EGFR phosphorylation on tyrosine residues Y1068 and Y1173. Compared with ibrutinib, acalabrutinib has much higher IC50(>1000 nM) or virtually no inhibition on kinase activities of ITK, EGFR, ERBB2, ERBB4, JAK3, BLK, FGR, FYN, HCK, LCK, LYN, SRC, and YES1.

In vivo: oral administration of ACP-196 in mice results in dose-dependent inhibition of anti-IgM-induced CD86 expression in CD19+ splenocytes with an ED50 of 0.34 mg/kg compared to 0.91 mg/kg for ibrutinib. A similar model is used to compare the duration of Btk inhibition after a single oral dose of 25 mg/kg. ACP-196 inhibits CD86 expression >90% at 3h postdose.

Chemical Information
Molecular Weight 465.51
Formula C26H23N7O2
CAS Number 1420477-60-6
Solubility (25°C) 80 mg/mL in DMSO
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] Wu J, et al. J Hematol Oncol. Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor.

[2] Byrd JC, et al. N Engl J Med. Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.

Related BTK Products
TL-925

TL-925 is a potentially first-in-class Bruton's tyrosine kinase (BTK) inhibitor that targets mast cell-mediated ocular inflammation and hypersensitivity and can be used in studies related to dry eye.

JAK3/BTK-IN-6

JAK3/BTK-IN-6 is a potent BTK and JAK3 dual inhibitor, with IC50 values of 0.6 and 0.4 nM, respectively.

NX-2127

NX-2127 is an orally active, potent BTK inhibitor that induces degradation of mutant BTKC481S in cells, as well as inhibits the proliferation of BTKC481S mutant TMD8 cells. In addition, NX-2127 stimulates T cell activation and increases IL-2 production in primary human T cells.

DBt-10

DBt-10 is a potent BTK degrader.

BTK-IN-27

BTK-IN-27 is a BTK inhibitor (IC50: 0.2 nM).

  Catalog
Abmole Inhibitor Catalog




Keywords: Acalabrutinib, ACP-196 supplier, BTK, inhibitors, activators


Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.